These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An update on managing patients with multiple sclerosis in primary care. Hardeman P JAAPA; 2024 Feb; 37(2):22-29. PubMed ID: 38230895 [TBL] [Abstract][Full Text] [Related]
4. Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis. Dimisianos N; Rodi M; Kalavrizioti D; Georgiou V; Papathanasopoulos P; Mouzaki A Mult Scler Int; 2014; 2014():436764. PubMed ID: 25152817 [TBL] [Abstract][Full Text] [Related]
5. Biomarkers of therapeutic response in multiple sclerosis: current status. Harris VK; Sadiq SA Mol Diagn Ther; 2014 Dec; 18(6):605-17. PubMed ID: 25164543 [TBL] [Abstract][Full Text] [Related]
8. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Freedman MS; Comi G; De Stefano N; Barkhof F; Polman CH; Uitdehaag BM; Lehr L; Stubinski B; Kappos L Mult Scler Relat Disord; 2014 Mar; 3(2):147-55. PubMed ID: 25878002 [TBL] [Abstract][Full Text] [Related]
9. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients. Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319 [TBL] [Abstract][Full Text] [Related]
10. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. Luchtman DW; Ellwardt E; Larochelle C; Zipp F Cytokine Growth Factor Rev; 2014 Aug; 25(4):403-13. PubMed ID: 25153998 [TBL] [Abstract][Full Text] [Related]
11. Recurrence of disease activity after repeated Natalizumab withdrawals. Ferrè L; Moiola L; Sangalli F; Radaelli M; Barcella V; Comi G; Martinelli V Neurol Sci; 2015 Mar; 36(3):465-7. PubMed ID: 25249399 [TBL] [Abstract][Full Text] [Related]
12. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496 [TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Fragoso YD Expert Opin Drug Saf; 2014 Dec; 13(12):1743-8. PubMed ID: 25176273 [TBL] [Abstract][Full Text] [Related]
14. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW; Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851 [TBL] [Abstract][Full Text] [Related]
15. Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Caporro M; Disanto G; Gobbi C; Zecca C Patient Prefer Adherence; 2014; 8():1123-34. PubMed ID: 25170258 [TBL] [Abstract][Full Text] [Related]